GREENVILLE, S.C., May 8 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that it will exhibit at the Heart Rhythm Society 28th Annual Scientific Sessions to be held May 9 - 12, 2007 at the Colorado Convention Center in Denver, Colorado. It is expected that the Heart Rhythm Meeting in 2007 will attract over 8,000 Heart Rhythm management professionals and 5,500 Heart Rhythm society members. The exhibit will provide unique exposure for Signalife to demonstrate its award wining technology and products.
To demonstrate the superiority of the Signalife technology, world-class athlete and Super Bowl winner Willie Gault of the 1985 Super Bowl Champions Chicago Bears will wear the Fidelity 100 and 300 devices while running on a treadmill at high speeds. The devices will garner clinical-quality ECG signals that will be displayed on a wide screen monitor for easy viewing. The demonstration will take place at the company’s booth #373 on both Thursday and Friday at 11am and 2pm.
“We are pleased to be exhibiting at Heart Rhythm 2007. The ACC 2007 presentation in March was extremely successful and our industry colleagues are aware of our capabilities to generate a high-fidelity ECG signal in a harsh environment. We are going to pursue different business opportunities for the best possible application of our technology. Our ultimate goal is to identify strategic partners, in addition to our already sizeable distribution channels, that can assist in the distribution of our technology for numerous applications. We made initial steps during and following the ACC Meeting and are hopeful to finalize certain business opportunities at Heart Rhythm 2007" stated Pamela Bunes, CEO, of Signalife, Inc.
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Kevin Kading, +1-212-918-4606, for Signalife, Inc.
Web site: http://www.signalife.com//
